BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36063639)

  • 1. Mathematical Models for Evaluating Effectiveness and Cost-Effectiveness of Cervical Cancer Control Policies in Populations Including Women Living With Human Immunodeficiency Virus: A Scoping Review.
    Iskandar R; Taghavi K; Low N; Bramer WM; Egger M; Rohner E
    Value Health Reg Issues; 2022 Nov; 32():39-46. PubMed ID: 36063639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine-grained mathematical modeling for cost-effectiveness evaluation of public health policies for cervical cancer, with application to a Colombian case study.
    Angulo D; Cortes MF; Mura I; Akhavan-Tabatabaei R
    BMC Public Health; 2023 Aug; 23(1):1470. PubMed ID: 37533028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
    van Schalkwyk C; Moodley J; Welte A; Johnson LF
    Int J Cancer; 2021 Oct; 149(8):1564-1575. PubMed ID: 34164807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
    Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies.
    Asangbeh-Kerman SL; Davidović M; Taghavi K; Kachingwe J; Rammipi KM; Muzingwani L; Pascoe M; Jousse M; Mulongo M; Mwanahamuntu M; Tapela N; Akintade O; Basu P; Dlamini X; Bohlius J
    BMC Public Health; 2022 Aug; 22(1):1530. PubMed ID: 35948944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination.
    Grimes DR; Corry EMA; Malagón T; O'Riain C; Franco EL; Brennan DJ
    JAMA Netw Open; 2021 Jun; 4(6):e2115321. PubMed ID: 34190993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study.
    Campos NG; Lince-Deroche N; Chibwesha CJ; Firnhaber C; Smith JS; Michelow P; Meyer-Rath G; Jamieson L; Jordaan S; Sharma M; Regan C; Sy S; Liu G; Tsu V; Jeronimo J; Kim JJ
    J Acquir Immune Defic Syndr; 2018 Oct; 79(2):195-205. PubMed ID: 29916959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
    Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
    Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
    Portnoy A; Pedersen K; Nygård M; Trogstad L; Kim JJ; Burger EA
    Med Decis Making; 2022 Aug; 42(6):795-807. PubMed ID: 35255741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of model-based cervical screening evaluations.
    Mendes D; Bains I; Vanni T; Jit M
    BMC Cancer; 2015 May; 15():334. PubMed ID: 25924871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis.
    Broshkevitch CJ; Barnabas RV; Liu G; Palanee-Phillips T; Rao DW
    PLoS One; 2024; 19(5):e0301997. PubMed ID: 38781268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of economic evaluations of cervical cancer screening methods.
    Sefuthi T; Nkonki L
    Syst Rev; 2022 Aug; 11(1):162. PubMed ID: 35945642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia.
    Setiawan D; Dolk FC; Suwantika AA; Westra TA; WIlschut JC; Postma MJ
    Value Health Reg Issues; 2016 May; 9():84-92. PubMed ID: 27881267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.